Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations…
Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ASCO abstract…
WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage…
Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy…
Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic…
Preliminary data from first 19 patients treated with PDS0101 in combination with KEYTRUDA® (pembrolizumab) demonstrates…
77% of checkpoint inhibitor (CPI) refractory patients alive at median follow up of 12 months…
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company…
Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with…
BOSTON, May 26, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical…
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical…
Overall response rate of 14% and disease control rate of 36% in Part B of…
Preclinical data from a study of the Company’s pan-RAF product candidate, KIN-2787, in combination with…
Clinically active and well tolerated in patients with solid tumors Favorable safety profile emerging: 22%…
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
– First clinical data demonstrating potential of SAFEbody technology platform to create…
Data demonstrate that SOT101 monotherapy and SOT101 in combination with pembrolizumab have a favorable safety…
– SRF388 demonstrated clinical activity in multiple solid tumor types withthree confirmed partial responses across…
SANTA ANA, Calif., May 26, 2022 (GLOBE NEWSWIRE) — NKGen Biotech Inc., a biotechnology company…
Results of open-label, multicenter study will be presented during a poster session at ASCO on…